Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : CardioDynamics (CDIC) -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (147)	5/22/2002 12:07:25 PM
From: tuck	Read Replies (2) \| Respond to of 201

>>SAN DIEGO--(BW HealthWire)--May 22, 2002--CardioDynamics (Nasdaq: CDIC - News), the innovator and global leader of Impedance Cardiography (ICG) technology and manufacturer of BioZ® noninvasive digital cardiac function monitoring systems, today announced the publication of a significant Mayo Clinic Study demonstrating the importance of the company's noninvasive ICG technology in the treatment of hypertension in the May 17, 2002 issue of the peer-reviewed journal, Hypertension. The Study demonstrated 70% superiority in effectively treating previously uncontrolled (also referred to as resistant) high blood pressure (hypertensive) patients with ICG, as compared to traditional management by high blood pressure specialist physicians. Hypertension, an American Heart Association journal, ranks 5th among the 45 journals in the peripheral vascular disease category and has a circulation of over 4,000 cardiologists, physiologists, endocrinologists, nephrologists and internists/primary care physicians. In the Study, one-half of the 104 resistant hypertension patients were treated with prescribed drugs based on traditional hypertension specialist evaluation, and one-half of the patients were treated with prescribed drugs based upon the BioZ's hemodynamic (blood flow) data. Within a three month period, the BioZ monitored-patient group reached goal (less than 140/90 mm Hg) blood pressure 70% more often than the patients being treated without BioZ data. The study's investigators concluded, "Our results demonstrate superior blood pressure control using a treatment algorithm and serial hemodynamic measurements compared with clinical judgment alone in a randomized prospective study." This Study supports the company's view that its ICG technology can play a significant role in fighting the war against blood pressure (HBP). According to the American Heart Association, 50 million Americans, one in four adults, have high HBP, and 26.2 percent are on medication, but uncontrolled. HBP has become a major public health concern, annually costing the U.S. approximately $37.2 billion. Prior to the advent of ICG, physicians were limited to basic clinical examination, which included blood pressure, examining neck veins, and relying on subjective patient data. ICG technology now provides clinicians with 12 parameters of objective data to enhance their understanding of the underlying causes of hypertension, select appropriate drugs, and decrease the time it takes to control the patient's blood pressure. "This publication provides additional scientific merit to the importance of our ICG technology in improving and advancing the treatment of high blood pressure patients," stated Michael K. Perry, CardioDynamics' chief executive officer. "Publications of ICG studies in peer-review medical journals, such as Hypertension, are invaluable to the exposure of ICG. Through streamlining and improving high blood pressure treatment with ICG, we hope to dramatically contribute to the reduction of cardiovascular disease, a disease from which one out of every two Americans die." The company also exhibited its ICG technology at the 17th Annual Scientific Meeting of the American Society of Hypertension, May 15-17, in New York. Over 50 sales leads were obtained at the meeting and will be aggressively pursued by the company's sales force. Additionally, the company met with the lead investigators of its Multi-Center Hypertension Study called "CONTROL" to finalize the protocol and determine the Study's test sites. The CONTROL Study will attempt to demonstrate that even greater than 70 percent improvements in BP control rates can be achieved when BioZ ICG data is utilized in a generalist physician practice treating more routine hypertension. Perry added, "We are pleased with the productive meetings that took place at the recent ASH meeting. We are continuing to develop initiatives to have our ICG technology included in National Treatment Guidelines, including the treatment of hypertension and congestive heart failure."<< snip Cheers, Tuck